Processa Pharmaceuticals (PCSA) officer adds 1,603-share open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Business & Strategy Officer Patrick Lin made an open-market purchase of 1,603 shares of common stock at $2.535 per share. Following this transaction, he directly holds 3,356 shares. In addition, 1,740 shares are held indirectly through the Lin Family Trust dated February 4, 2024.

Insider Trade Summary

Net Buyer: 1,603 shares ($4,064)

Net Buy 2 txns

Insider Lin Patrick

Role Chief Business - Strategy Off

Bought 1,603 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,603	$2.535	$4K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,356 shares (Direct); Common Stock — 1,740 shares (Indirect, Lin Family Trust Feb 4, 2024)

Footnotes (1)

Key Figures

Shares purchased: 1,603 shares Purchase price: $2.535 per share Direct holdings after transaction: 3,356 shares +1 more

4 metrics

Shares purchased 1,603 shares Open-market purchase of common stock on March 31, 2026

Purchase price $2.535 per share Price paid for Processa common stock in open-market trade

Direct holdings after transaction 3,356 shares Patrick Lin’s directly owned Processa common stock post-transaction

Indirect holdings after transaction 1,740 shares Shares held via Lin Family Trust dated February 4, 2024

Key Terms

open-market purchase, indirect ownership, Lin Family Trust Feb 4, 2024, Form 4

4 terms

open-market purchase financial

"transaction_action":"open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

""direct_or_indirect":"I","nature_of_ownership""

Lin Family Trust Feb 4, 2024 financial

""nature_of_ownership":"Lin Family Trust Feb 4, 2024""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Patrick

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business - Strategy Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		P		1,603	A	$2.535	3,356	D
Common Stock								1,740	I	Lin Family Trust Feb 4, 2024

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Processa Pharmaceuticals (PCSA) officer Patrick Lin do in this Form 4?

Patrick Lin reported an open-market purchase of Processa Pharmaceuticals common stock. He bought 1,603 shares on March 31, 2026, and now directly holds 3,356 shares, with an additional 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024.

How many Processa Pharmaceuticals (PCSA) shares did Patrick Lin buy and at what price?

Patrick Lin bought 1,603 shares of Processa Pharmaceuticals common stock. The open-market purchase price was $2.535 per share, indicating a relatively small personal investment and modest increase in his directly held position in the company’s stock.

What are Patrick Lin’s direct Processa Pharmaceuticals (PCSA) holdings after this transaction?

After the reported open-market purchase, Patrick Lin directly holds 3,356 shares of Processa Pharmaceuticals common stock. This total reflects the addition of 1,603 newly purchased shares to his previously held direct position reported in the Form 4 filing.

Does Patrick Lin have any indirect ownership of Processa Pharmaceuticals (PCSA) shares?

Yes. In addition to his direct holdings, 1,740 shares of Processa Pharmaceuticals common stock are held indirectly through the Lin Family Trust dated February 4, 2024. This trust-related position is reported as indirect ownership in the Form 4 filing.

Is the Form 4 transaction for Processa Pharmaceuticals (PCSA) a buy or a sell?

The Form 4 shows a buy transaction. Patrick Lin executed an open-market purchase of 1,603 shares of Processa Pharmaceuticals common stock at $2.535 per share, increasing his directly owned stake in the company according to the filing details.